Skip to main content
. Author manuscript; available in PMC: 2019 Sep 16.
Published in final edited form as: J Neuroimmune Pharmacol. 2016 Apr 16;11(2):369–377. doi: 10.1007/s11481-016-9670-0

Fig. 2.

Fig. 2

Lesional area in a sensitized CCM murine model after B cell depletion. a Anti-BR3 antibody treatment of Pdcd10+/−Trp53−/− mice significantly reduced the area of mature stage 2 lesions, but did not affect the area of stage 1 pre-lesions. Horizontal lines indicate the mean (longer lines) and standard error of the mean (shorter lines). b Representative largest lesions are shown from treated and untreated mice at the same magnification (these do not represent the same brain regions). Scale bars are 1 mm